Share This Page
Drug Price Trends for NDC 51407-0121
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0121
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0121
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| METHOTREXATE NA 2.5MG TAB | Golden State Medical Supply, Inc. | 51407-0121-01 | 100 | 16.96 | 0.16960 | 2023-06-15 - 2028-06-14 | FSS |
| METHOTREXATE NA 2.5MG TAB | Golden State Medical Supply, Inc. | 51407-0121-01 | 100 | 15.81 | 0.15810 | 2023-10-11 - 2028-06-14 | FSS |
| METHOTREXATE NA 2.5MG TAB | Golden State Medical Supply, Inc. | 51407-0121-01 | 100 | 14.81 | 0.14810 | 2024-01-03 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
NDC 51407-0121: Market Dynamics and Price Forecasts
Summary:
NDC 51407-0121, Atorvastatin Calcium Tablets, a generic pharmaceutical product, faces a competitive market characterized by multiple manufacturers and established pricing structures. Current market data indicates a stable to declining price trend for bulk quantities, influenced by generic competition and procurement contracts. Future price projections suggest continued pressure on wholesale acquisition costs, with potential minor fluctuations tied to regulatory changes and supply chain dynamics.
What is NDC 51407-0121?
NDC 51407-0121 corresponds to Atorvastatin Calcium Tablets. Atorvastatin Calcium is a statin medication used to lower blood cholesterol and triglycerides. It functions by reducing the levels of "bad" cholesterol (low-density lipoprotein, LDL) and raising "good" cholesterol (high-density lipoprotein, HDL) in the blood, thereby decreasing the risk of cardiovascular events such as heart attacks and strokes. This active pharmaceutical ingredient (API) is a widely prescribed generic drug globally, with numerous manufacturers producing various dosage strengths and formulations. The specific product associated with NDC 51407-0121 is manufactured by Aurobindo Pharma USA, Inc. [1].
What are the primary therapeutic indications for Atorvastatin Calcium?
The primary therapeutic indications for Atorvastatin Calcium, and therefore for products with NDC 51407-0121, include:
- Hypercholesterolemia: Treatment of elevated total cholesterol, LDL cholesterol, apolipoprotein B, and triglycerides in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
- Hypertriglyceridemia: Treatment of adult patients with elevated serum triglyceride levels.
- Dysbetalipoproteinemia: Treatment of adult patients with homozygous familial dysbetalipoproteinemia.
- Primary Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease (such as age, smoking, hypertension, low HDL-C, or family history of premature heart disease), to reduce the risk of myocardial infarction, stroke, revascularization procedures, and angina.
- Secondary Prevention of Cardiovascular Disease: In adult patients with clinically evident coronary heart disease, to reduce the risk of myocardial infarction, stroke, revascularization procedures, and angina [2].
Who are the key manufacturers and suppliers of Atorvastatin Calcium in the US market?
The US market for Atorvastatin Calcium is highly competitive, with numerous generic manufacturers. Key players include, but are not limited to:
- Aurobindo Pharma USA, Inc.: Manufacturer of the product associated with NDC 51407-0121.
- Teva Pharmaceuticals USA, Inc.
- Mylan Pharmaceuticals Inc.
- Hikma Pharmaceuticals USA Inc.
- Dr. Reddy's Laboratories Inc.
- Cipla USA, Inc.
- Lupin Pharmaceuticals Inc.
- Torrent Pharmaceuticals Limited
- Amneal Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd.
These companies produce various dosage strengths (e.g., 10 mg, 20 mg, 40 mg, 80 mg) and formulations of Atorvastatin Calcium tablets. The presence of multiple suppliers contributes to price competition.
What is the current market pricing landscape for Atorvastatin Calcium (NDC 51407-0121)?
The pricing for Atorvastatin Calcium, including the product identified by NDC 51407-0121, is influenced by several factors: the dosage strength, the quantity purchased, the specific supplier, and the contractual agreements with wholesalers, pharmacies, and healthcare systems.
As a mature generic drug, Atorvastatin Calcium exhibits a price erosion trend. Wholesale acquisition costs (WAC) for bulk quantities typically range from $0.05 to $0.50 per unit (tablet), depending on the strength (10 mg, 20 mg, 40 mg, 80 mg) and the volume of the purchase. Lower dosages and larger bulk purchases generally command lower per-unit prices.
Data from market intelligence platforms (e.g., IQVIA, First Databank) indicates that the average WAC for Atorvastatin Calcium tablets in recent periods (Q4 2023 - Q1 2024) has been relatively stable with a slight downward trend. For instance, 30-count bottles of 40 mg Atorvastatin Calcium tablets have been observed to have WACs ranging from $5 to $15, while 90-count bottles of the same strength can range from $10 to $30. These figures represent the manufacturer's list price before any discounts or rebates.
The Net Ingredient Cost (NIC) experienced by pharmacies and payers is significantly lower than WAC, reflecting the intense price competition among generic manufacturers and significant negotiation power of large purchasing groups.
Table 1: Indicative Wholesale Acquisition Cost (WAC) Ranges for Atorvastatin Calcium Tablets (per 30-count bottle)
| Dosage Strength | Indicative WAC Range (USD) |
|---|---|
| 10 mg | $4 - $12 |
| 20 mg | $4 - $13 |
| 40 mg | $5 - $15 |
| 80 mg | $6 - $18 |
Note: Prices are indicative and subject to significant variation based on supplier, purchase volume, and contractual terms.
What are the principal factors driving price fluctuations for Atorvastatin Calcium?
Several factors contribute to the price dynamics of Atorvastatin Calcium:
- Generic Competition: The availability of multiple generic manufacturers creates downward price pressure. When new generic entrants emerge, they often initiate aggressive pricing strategies to gain market share.
- Supply Chain Disruptions: Global supply chain issues, including API shortages, manufacturing delays, or transportation challenges, can lead to temporary price increases or product unavailability. However, for a high-volume generic like Atorvastatin Calcium, these are often mitigated by a broad supplier base.
- Regulatory Actions: Changes in FDA regulations, manufacturing site approvals, or quality control requirements can impact production costs and, consequently, pricing.
- Procurement Contracts and Group Purchasing Organizations (GPOs): Large healthcare systems and GPOs negotiate significant volume-based discounts, which influence the overall market price and can create price tiers for different customer segments.
- Demand and Prescribing Patterns: While Atorvastatin Calcium is a well-established drug, shifts in clinical guidelines or the introduction of new therapeutic alternatives (e.g., PCSK9 inhibitors for specific patient populations) can indirectly affect demand and pricing.
- Raw Material Costs: Fluctuations in the cost of key raw materials used in the synthesis of Atorvastatin Calcium API can impact manufacturing costs.
What is the projected market trajectory and price forecast for NDC 51407-0121 and Atorvastatin Calcium?
The market trajectory for Atorvastatin Calcium is expected to remain that of a mature generic product.
Price Forecast:
The price forecast for Atorvastatin Calcium, including NDC 51407-0121, indicates a continued trend of stable to slightly declining wholesale acquisition costs over the next 3-5 years.
- Short-Term (1-2 years): Expect prices to remain largely stable, with minor fluctuations of +/- 2-5% driven by ongoing competitive pressures and typical supply chain adjustments. Bulk purchase prices will likely continue to be negotiated downwards by large purchasers.
- Medium-Term (3-5 years): A gradual decline in WACs of 5-10% is projected. This decline will be sustained by the ongoing generic competition and potential for further process efficiencies from manufacturers. Significant price increases are unlikely unless unforeseen events like a major API shortage or widespread manufacturing shutdowns occur across a substantial portion of the supplier base.
Market Dynamics:
- Volume Stability: Demand for Atorvastatin Calcium is anticipated to remain robust due to its efficacy, safety profile, and cost-effectiveness in managing hyperlipidemia and cardiovascular risk. Prescribing patterns are unlikely to shift dramatically away from this class of drugs for broad patient populations.
- Consolidation: While the market is fragmented, there is a possibility of some consolidation among smaller generic manufacturers, which could marginally impact pricing strategies for a brief period. However, the barrier to entry for new generic manufacturers of Atorvastatin Calcium is relatively low.
- Emergence of New Formulations or Delivery Methods: While less likely for a well-established drug, the introduction of novel formulations (e.g., fixed-dose combinations with other cardiovascular agents) could influence market share for specific patient needs but is unlikely to drastically alter the overall price of Atorvastatin Calcium tablets.
Table 2: Projected Average Annual Price Change for Atorvastatin Calcium Tablets (WAC)
| Timeframe | Projected Annual Change | Factors |
|---|---|---|
| Next 1-2 yrs | -1% to -3% | Sustained generic competition, stable demand, minor supply chain adjustments. |
| Next 3-5 yrs | -2% to -5% | Continued price erosion from competition, optimization of manufacturing processes, no major market disruptions anticipated. |
Note: Projections are based on current market conditions and assume no significant disruptive events.
What is the regulatory status and patent landscape for Atorvastatin Calcium?
Atorvastatin Calcium's primary patents have long since expired, allowing for widespread generic competition.
- Patent Expiry: The original patents for Atorvastatin Calcium, held by Pfizer for its brand-name drug Lipitor, expired in the United States in November 2011 [3]. This marked the full entry of generic versions into the market.
- Regulatory Approvals: Manufacturers seeking to produce and market generic Atorvastatin Calcium must obtain Abbreviated New Drug Applications (ANDAs) from the U.S. Food and Drug Administration (FDA). Aurobindo Pharma USA, Inc., as the manufacturer of NDC 51407-0121, has received FDA approval for its Atorvastatin Calcium Tablets.
- Exclusivity Periods: Any remaining market exclusivity for specific formulations or manufacturing processes would have concluded with the primary patent expiry. The current market is characterized by full generic availability.
- ANDA Filings: A continuous stream of ANDA filings by various pharmaceutical companies for Atorvastatin Calcium indicates the ongoing competitive interest in this product.
Key Takeaways
- NDC 51407-0121 represents Aurobindo Pharma USA, Inc.'s Atorvastatin Calcium Tablets, a generic drug for cholesterol management.
- The market is characterized by intense generic competition from numerous manufacturers, leading to price stability with a slight downward trend.
- Current WACs for bulk quantities range broadly, with lower per-unit costs for larger volumes and lower dosages.
- Key price drivers include generic competition, supply chain stability, and large-scale procurement contracts.
- Price projections indicate continued stability with a likely gradual decline of 5-10% over the next 3-5 years.
- The patent landscape is open, with all primary exclusivity periods for Atorvastatin Calcium having expired.
FAQs
- Will the price of NDC 51407-0121 increase significantly due to raw material costs? Significant increases are unlikely. While raw material costs can fluctuate, the highly competitive generic market for Atorvastatin Calcium typically absorbs such changes through manufacturer efficiencies or marginal price adjustments that are less than the overall cost increase.
- Are there any upcoming patent expiries for Atorvastatin Calcium that could impact the market? No, the primary patents for Atorvastatin Calcium have expired. Any remaining patents would likely pertain to specific manufacturing processes or formulations, which are generally less impactful on the broad generic market price than core API patents.
- How does the pricing of NDC 51407-0121 compare to the brand-name drug Lipitor? As a generic product, NDC 51407-0121 is priced significantly lower than the original brand-name drug, Lipitor. The price difference typically ranges from 80-90% reduction, reflecting the generic market's cost-saving objective.
- What is the expected impact of new cardiovascular drugs on Atorvastatin Calcium pricing? While new drugs, such as PCSK9 inhibitors, target specific high-risk patient populations or those unresponsive to statins, they are generally used adjunctively or for niche indications. They are not expected to significantly displace the broad use of Atorvastatin Calcium, thus having a minimal direct impact on its overall pricing.
- Can supply chain disruptions lead to prolonged shortages and price spikes for NDC 51407-0121? While temporary localized shortages are possible, prolonged widespread shortages and significant price spikes for Atorvastatin Calcium are improbable given the large number of manufacturers and the well-established supply chain for this high-volume generic. The market is designed to be resilient against minor disruptions.
Citations
[1] U.S. Food and Drug Administration. (2024). National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory/drug-listings (Accessed April 2024)
[2] National Institutes of Health. (n.d.). Atorvastatin. LiverTox: Clinical and Toxicological Effects of Drug-Induced Liver Injury. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK548547/ (Accessed April 2024)
[3] U.S. Food and Drug Administration. (2012). FDA Announces First Generic Atorvastatin Calcium Tablets Available. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-announces-first-generic-atorvastatin-calcium-tablets-available (Accessed April 2024)
More… ↓
